CareerExamPro

NAPLEX/MPJE Pharmacy Law, Calculations & ASQ Quality Engineering practice questions

20 questions from the RAPS RAC, ACRP/SOCRA, MPJE & ASQ CQE practice test.

Start practising

NAPLEX/MPJE Pharmacy Law, Calculations & ASQ Quality Engineering practice drill

10 realistic exam questions, graded as you go, with the exact rule or statute citation for every answer. Start free, no sign-up.

Sample questions

A retail pharmacy receives a valid Schedule II prescription for 60 tablets of oxycodone 10 mg for an outpatient who is neither terminally ill nor residing in a Long-Term Care Facility (LTCF). Because the pharmacy has only 20 tablets in stock, the pharmacist dispenses 20 tablets on Monday at 10:00 AM after confirming the patient agrees to wait for the remainder. Under federal Controlled Substances Act regulations (21 CFR 1306.13), what rule governs dispensing the remaining 40 tablets?

  1. The remaining 40 tablets may be filled anytime within 30 days of the issue date, matching patient-requested partial fills.
  2. The remaining 40 tablets must be filled within 72 hours, or the prescriber must be notified and the balance voided.
  3. The remaining 40 tablets may be dispensed over multiple increments for up to 60 days from the issue date with prescriber notice.
  4. Federal CSA rules prohibit any partial dispensing of Schedule II prescriptions for out-of-stock shortages, requiring a new order.
Show the answer

B. The remaining 40 tablets must be filled within 72 hours, or the prescriber must be notified and the balance voided.

Under 21 CFR 1306.13(a), when a pharmacy is unable to supply the full quantity of a Schedule II prescription (out of stock), the remaining portion must be supplied within 72 hours of the first partial filling; if the balance cannot be supplied within 72 hours, the pharmacist must notify the prescriber and no further quantity may be supplied without a new prescription. By contrast, patient- or prescriber-requested partial fills under 21 CFR 1306.13(b) (CARA) allow the remainder within 30 days of the issue date, and LTCF or terminally ill patient C-II partial fills are valid for up to 60 days from the issue date.

Reference: 21 CFR 1306.13(a)–(c) (Federal CSA Partial Filling of Schedule II Prescriptions)

A hospital pharmacy receives a shipment of high-cost oncology biologics from an authorized wholesale distributor. During receiving verification under the Drug Supply Chain Security Act (DSCSA), the pharmacy technician detects tampered seals and a 2D GS1 DataMatrix product identifier whose serial number does not match the manufacturer's verification database. Subsequent investigation confirms the product is counterfeit (illegitimate). What mandatory DSCSA actions and timelines apply?

  1. Quarantine the vials, notify FDA (Form 3911) and immediate trading partners within 24 hours, and retain records for 6 years.
  2. Return the counterfeit vials to the wholesaler for credit within 72 hours and notify FDA only if a patient receives a dose.
  3. Quarantine the vials, notify FDA within 15 calendar days via MedWatch Form 3500A, and retain transaction records for 2 years.
  4. Destroy the vials immediately using DEA Form 41 to prevent diversion, then file an annual report with the State Board of Pharmacy.
Show the answer

A. Quarantine the vials, notify FDA (Form 3911) and immediate trading partners within 24 hours, and retain records for 6 years.

Under DSCSA (FDCA Section 582), trading partners must verify product identifiers (NDC, serial number, lot number, and expiration date in a 2D DataMatrix barcode) and immediately quarantine any suspect product during investigation. Once a product is determined to be illegitimate (e.g., counterfeit, diverted, or stolen), the dispenser must notify FDA (via Form FDA 3911) and all immediate trading partners that may have received it within 24 hours of making the determination, and must retain investigation and transaction records for at least 6 years.

Reference: FDCA § 582 (Drug Supply Chain Security Act — Suspect & Illegitimate Product Requirements)

On Sunday evening, a physician calls a community pharmacy to authorize an emergency oral Schedule II prescription for immediate-release morphine sulfate for an acute pain crisis when no alternative treatment is available. Under 21 CFR 1306.11(d), what must the pharmacist and prescriber do to remain compliant with federal CSA regulations?

  1. Dispense up to a 30-day supply on oral authorization and obtain a follow-up written prescription within 15 calendar days.
  2. Refuse all oral Schedule II authorizations completely, since federal law restricts verbal C-II orders to hospice inpatients.
  3. Dispense an emergency supply only after faxing DEA Form 222 and receiving an electronic cover prescription within 72 hours.
  4. Dispense only the quantity adequate for the emergency, reduce it to writing at once, and receive a cover script within 7 days.
Show the answer

D. Dispense only the quantity adequate for the emergency, reduce it to writing at once, and receive a cover script within 7 days.

Under 21 CFR 1306.11(d), in an emergency situation a pharmacist may dispense a Schedule II controlled substance upon receiving oral authorization from a prescribing practitioner, strictly limited to the amount adequate to treat the patient during the emergency period. The pharmacist must immediately reduce the prescription to writing, and the prescriber must deliver a signed written (or compliant electronic) cover prescription labeled 'Authorization for Emergency Dispensing' with the date of the oral order within 7 days (postmarked within 7 days if mailed). If not received within 7 days, the pharmacist must notify the nearest DEA office.

Reference: 21 CFR 1306.11(d) (Emergency Oral Schedule II Prescriptions)

Other topics